HLB bioStep, a Korean non-clinical CRO, said Friday that it has acquired Croen, a company specializing in GLP (Good Laboratory Practice) toxicity testing.
 

Through this acquisition, HLB bioStep will provide integrated nonclinical services for drug development by securing the capability to conduct various GLP toxicity tests, including general toxicity, immunotoxicity, genotoxicity, and topical toxicity, in addition to its existing validation services.
 

Please refer to the following website for further details : HLB bioStep acquires GLP toxicology testing firm Croen